Implantable cardiac stimulating device and method for administering synchronized cardioversion shock therapy to provide preemptive depolarization
 An implantable cardioversion shock therapy system is provided which delays delivery of a cardioversion shock until late in the cardiac cycle to optimize the chance for the vast majority of ventricular myocardial tissue to be non-refractory. The system in intended to increase efficacy and safety by properly synchronizing the cardioversion shock to the appropriate portion of the cardiac cycle to successfully terminate a tachycardia episode. The timing of the cardioversion shock is programmable as either a percentage of measured tachycardia cycle length or fixed delay in milliseconds. 
Pacesetter, Inc.
A
A61N
inventional
James L.
Duncan